The financing will be used to hire additional team members and conduct additional studies in fertility science. The firm also launched its $199 fertility test.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Participants in the financing round included CS Investors, Pivotal Paramount Investment, and Stanford University.
The firm said that its technology enables the detection of rare DNA variants with high accuracy to enable liquid biopsy diagnosis and treatments for multiple diseases.
The company will use the funding to advance the commercialization of its proprietary liquid biopsy technology.
The financing will go toward development of the company's home-based testing technology, which will be initially targeted at fertility testing.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.